rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
The study is designed as a randomized, two-armed, double-blind, single-dose, crossover, two-sequence, active-controlled, multi-center, bioequivalence clinical trial with a primary endpoint of dose-normalized area under the curve (dnAUC last)
Epistemonikos ID: 68ec1fd2dcbeb4cda3b61ac818ffce73c7123ac9
First added on: May 15, 2024